Investing in Hyperbaric Oxygen Therapy: Market Size, Growth, and the RxAir360 Opportunity

Healthcare infrastructure follows a pattern. A treatment modality begins in hospitals, concentrated in specialized centers, accessible only to patients who live near major medical facilities or can afford to travel.

Then something changes. Technology improves. Reimbursement frameworks mature. Device engineering solves the infrastructure problem. And the treatment moves into the community — into physician offices, outpatient clinics, and the point of care where patients already receive treatment.

Every time this has happened in healthcare, the market expanded dramatically. Dialysis. Imaging. Ambulatory surgery. The story is the same each time.

Hyperbaric oxygen therapy is at the beginning of that transition. The clinical case is established — 14 FDA-cleared indications, Medicare coverage, 60-plus years of peer-reviewed research. What has been missing is the infrastructure to deliver it outside hospital settings. That is the gap RxAir360 was designed to close.

HBOT Market Size and Growth Forecast 2026–2030

The global hyperbaric oxygen therapy market has been the subject of multiple independent analyst projections, all pointing in the same direction.

Current market size

The global HBOT devices market was valued at approximately $3.7 to $4.1 billion in 2024 across major analyst forecasts, encompassing chamber sales, clinical services, and related consumables. The United States represents the largest single market, driven by Medicare reimbursement for FDA-cleared indications and the existing hospital-based clinical infrastructure.

Growth drivers

Analysts consistently cite four primary factors driving HBOT market growth through 2030:

• •Aging population — the primary demographic for HBOT's highest-volume indications (diabetic wound care, radiation injury) is growing rapidly as baby boomers age into Medicare eligibility
• •Diabetes prevalence — the CDC projects 55 million Americans will have diabetes by 2030, expanding the wound care indication patient pool significantly
• •Expanding indication research — clinical research into TBI, PTSD, stroke recovery, long COVID, and neurological conditions is broadening awareness and driving demand beyond traditional wound care applications
• •Infrastructure expansion — physician-office deployable systems like the RxAir360 chamber represent the mechanism through which HBOT access scales from 1,400 facilities to a much larger number of delivery points

Projected market size

Multiple independent analyst projections place the global HBOT devices market at $5 billion or above by 2030. Grand View Research estimates the market reaching $5.19 billion by 2030 at a CAGR of 5.8%; Precedence Research projects $6.71 billion by 2034. The compound annual growth rate across forecasters ranges from approximately 6 to 9 percent. The physician-office deployment segment — currently essentially zero — represents the largest untapped growth category within that projection.

Why Patented Technology Matters — RxAir360's Protected Position

In medical device markets, intellectual property is the competitive moat. A company with a cleared, patented device occupies a defensible market position that cannot be easily replicated. This is particularly true in a niche market where the engineering problem — fitting a clinical-grade hyperbaric chamber into a standard physician exam room — has not previously been solved.

RxAir360 holds an issued U.S. patent covering the vertical monoplace HBOT system designed for standard physician exam rooms. This patent protects:

• •The vertical, seated-upright chamber orientation — the design decision that makes exam-room deployment possible
• •The compact footprint engineering — the specific dimensional solution that fits the 10×12 foot constraint
• •The physician-office integration model — the system approach to outpatient clinical deployment

A competitor cannot build a vertical physician-office monoplace chamber without navigating RxAir360's patent position. This protection is in place before FDA clearance — before commercial launch — giving RxAir360 a head start that compounds as the market develops.

FDA 510(k) Pathway — What Clearance Means for Market Entry

FDA 510(k) clearance is the regulatory pathway for medical devices that are substantially equivalent to a legally marketed predicate device. For RxAir360, clearance is the gateway to commercial launch — it is not optional, and obtaining it is a prerequisite for everything that follows.

What clearance enables

• •Commercial sale and clinical use of the RxAir360 chamber in physician offices and clinical settings
• •Medicare and insurance billing for HBOT services delivered using the cleared device
• •Activation of professional sports organization deployment pipeline
• •Full OTC Markets public listing progression
• •Scaling of the physician-office deployment model nationally

Current status

The RxAir360 FDA 510(k) submission is in process. The chamber is designed in alignment with ASME PVHO-1, IEC 60601-1, and NFPA 99 standards — the same frameworks that govern existing cleared hyperbaric devices. The regulatory pathway is defined. The engineering work has been done. Clearance is the next milestone.

Pre-clearance positioning

RxAir360 has made a deliberate strategic decision to build its SEO, investor relations, and market presence ahead of FDA clearance — because SEO takes 3 to 6 months to build momentum. By the time clearance is announced, Google will already know who RxAir360 is. The announcement will land on a digital foundation that has been building authority for months. This is the same principle that drives every other pre-launch marketing investment: you build the platform before you need it.